Hepatitis B and renal transplantation: Securing the sword of Damocles
2002; Lippincott Williams & Wilkins; Volume: 36; Issue: 5 Linguagem: Inglês
10.1053/jhep.2002.36805
ISSN1527-3350
Autores Tópico(s)Liver Disease Diagnosis and Treatment
ResumoHepatologyVolume 36, Issue 5 p. 1041-1045 EditorialsFree Access Hepatitis B and renal transplantation: Securing the sword of Damocles Robert P. Perrillo M.D., Corresponding Author Robert P. Perrillo M.D. [email protected] From the Section of Gastroenterology and Hepatology, Ochsner Clinic Foundation, New Orleans, LAOchsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70124. fax: 504-842-7466.===Search for more papers by this author Robert P. Perrillo M.D., Corresponding Author Robert P. Perrillo M.D. [email protected] From the Section of Gastroenterology and Hepatology, Ochsner Clinic Foundation, New Orleans, LAOchsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70124. fax: 504-842-7466.===Search for more papers by this author First published: 30 December 2003 https://doi.org/10.1053/jhep.2002.36805Citations: 20AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Pirson Y, Alexandre GPJ, van Ypersele de Strihou C. Long-term effect of HBs antigenemia on patient survival after renal transplantation. N Engl J Med 1977; 296: 194– 196.MEDLINE 2 Parfrey PS, Forbes RDC, Hutchinson TA, Beaudoin JG, Dauphinee WD, Hollomby DJ, Guttmann RD. The clinical and pathological course of hepatitis B liver disease in renal transplant recipients. Transplantation 1984; 37: 461– 466.MEDLINE 3 Degos F, Lugassy C, Degott C, Debure A, Carnot F, Thiers V, Tiollais P, et al. Hepatitis B virus and hepatitis B-related viral infection in renal transplant recipients. A prospective study of 90 patients. Gastroenterology 1988; 94: 151– 156.MEDLINE 4 Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, Thibault V, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29: 257– 263.MEDLINE 5 Madayag RM, Johnson LB, Bartlett ST, Schweitzer EJ, Constantine NT, McCarter RJ, Kuo PC, et al. Use of renal allografts from donors positive for hepatitis B core antibody confers minimal risk for subsequent development of clinical hepatitis B virus disease. Transplantation 1997; 64: 1781– 1786.MEDLINE 6 Fong T-L, Bunnapradist S, Jordan SC, Cho YW. Impact of hepatitis B core antibody status on outcomes of cadaveric renal transplantation: analysis of United Network of Organ Sharing database between 1994 and 1999. Transplantation 2002; 73: 85– 89.MEDLINE 7 Ramos EL, Kasiske BL, Alexander SR, Danovitch GM, Harmon WE, Kahana L, Kiresuk TJ, et al. The evaluation of candidates for renal transplantation. The current practice of U.S. transplant centers. Transplantation 1994; 57: 490– 497.MEDLINE 8 Rodrigues A, Morgado T, Areias J, Silvestre F, Pinho L, Alves H, Castro-Henriques A, et al. Limited benefits of IFN-α therapy in renal graft candidates with chronic viral hepatitis B or C. Transplant Proc 1997; 29: 777– 780.MEDLINE 9 Monteon FJ, Contreras AM, Espinoza L, Vazquez G, Aguilar S, Cueva L. Interferon alfa-2b in renal transplant recipients with viral chronic hepatitis: a pilot study. Transplant Proc 1996; 28: 3306– 3308.MEDLINE 10 Kramer P, ten Kate FW, Bijnen AB, Jeekel J, Weimar W. Recombinant leucocyte interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients. Lancet 1984; 1: 989– 990.MEDLINE 11 Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence. MMWR Recomm Rep 1993; 42(RR-4): 1– 18. 12 Pesanti EL. Immunologic defects and vaccination in patients with chronic renal failure. Infect Dis Clin North Am 2001; 15: 813– 832.MEDLINE 13 Park S-K, Yang WS, Lee YS, Jung HH, Chang JW, Choi HJ, Han DJ, et al. Outcome of renal transplantation in hepatitis B surface antigen-positive patients after introduction of lamivudine. Nephrol Dial Transplant 2001; 16: 2222– 2228.MEDLINE 14 Mosconi G, Scolari MP, Manna C, Canova C, Cristino S, Campieri C, D'Arcangelo L, et al. Lamivudine in recurrent hepatitis B after renal transplantation. Transplant Proc 2001; 33: 1873– 1874.MEDLINE 15 Lee W-C, Wu M-J, Cheng C-H, Chen C-H, Shu K-H, Lian J-D. Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients. Am J Kidney Dis 2001; 38: 1074– 1081.MEDLINE 16 Lewandowska D, Durlik M, Kukula K, Cieciura T, Ciecierski R, Walewska-Zielecka B, Szmidt J, et al. Treatment of chronic hepatitis B with lamivudine in renal allograft recipients. Transplant Proc 2000; 32: 1369– 1370.MEDLINE 17 Antoine C, Landau A, Menoyo V, Duong JP, Duboust A, Glotz D. Efficacy and safety of lamivudine in renal transplant patients with chronic hepatitis B. Transplant Proc 2000; 32: 384– 385.MEDLINE 18 Mouquet C, Bernard B, Poynard T, Thibault V, Opolon P, Coriat P, Bitker MO. Chronic hepatitis B treatment with lamivudine in kidney transplant patients. Transplant Proc 2000; 32: 2762.MEDLINE 19 Tsai M-K, Lai M-Y, Hu R-H, Lee C-J, Lee P-H. Managing hepatitis B reactivation in renal transplant recipients: a 12-year review with emphasis on early detection and early use of lamivudine. Transplant Proc 2000; 32: 1935– 1936.MEDLINE 20 Kletzmayr J, Watschinger B, Muller C, Demetriou D, Puchhammer-Stockl E, Ferenci P, Kovarik J. Twelve months of lamivudine treatment for chronic hepatitis B virus infection in renal transplant recipients. Transplantation 2000; 70: 1404– 1407.MEDLINE 21 Goffin E, Horsmans Y, Cornu C, Squifflet J-P, Pirson Y. Lamivudine inhibits hepatitis B virus replication in kidney graft recipients. Transplantation 1998; 66: 407– 409.MEDLINE 22 Jung YO, Lee YS, Yang WS, Han DJ, Park JS, Park S-K. Treatment of chronic hepatitis B with lamivudine in renal transplant recipients. Transplantation 1998; 66: 733– 737.MEDLINE 23 Rostaing L, Henry S, Cisterne J-M, Duffaut M, Icart J, Durand D. Efficacy and safety of lamivudine on replication of recurrent hepatitis B after cadaveric renal transplantation. Transplantation 1997; 64: 1624– 1627.MEDLINE 24 Pol S, Saltiel C, Legendre C, Carnot F, Driss F, Berthelot P, Brechot C, et al. Efficacy of adenine arabinoside 5'-monophosphate in kidney recipients with chronic active hepatitis B: a pilot study. Transplant Proc 1993; 25: 1446– 1449.MEDLINE 25 Garnier J-L, Chossegros P, Daoud S, Chevallier P, Dubernard J-M, Trepo C, Touraine J-L. Treatment of hepatitis B virus replication by ganciclovir in kidney transplant patients. Transplant Proc 1997; 29: 817.MEDLINE 26 Tang S, Ho SKN, Moniri K, Lai KN, Chan TM. Efficacy of famciclovir in the treatment of lamivudine resistance related to an atypical hepatitis B virus mutant. Transplantation 2002; 73: 148– 151.MEDLINE 27 Faraidy KA, Yoshida EM, Davis JE, Vartanian RK, Anderson FH, Steinbrecher UP. Alteration of the dismal natural history of fibrosing cholestatic hepatitis secondary to hepatitis B virus with the use of lamivudine. Transplantation 1997; 64: 926– 928.MEDLINE 28 Chan T-M, Wu P-C, Li F-K, Lai C-L, Cheng IKP, Lai K-N. Treatment of fibrosing cholestatic hepatitis with lamivudine. Gastroenterology 1998; 115: 177– 181.MEDLINE 29 Chan TM, Fang GX, Tang CSO, Cheng IKP, Lai KN, Ho SKN. Pre-emptive lamivudine therapy based on HBV DNA in HBsAg-positive kidney allograft recipients. Hepatology 2002; 36: 1246– 1252. 30 Perrillo R. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001; 120: 1009– 1022.MEDLINE 31 Fontaine H, Thiers V, Chretien Y, Zylberberg H, Poupon RE, Brechot C, Legendre C, et al. HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients. Transplantation 2000; 69: 2090– 2094.MEDLINE 32 Peters MG, Singer G, Howard T, Jacobsmeyer S, Xiong X, Gibbs CS, Lamy P, et al. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin. Transplantation 1999; 68: 1912– 1914.MEDLINE 33 Mutimer D, Pillay D, Shields P, Cane P, Ratcliffe D, Martin B, Buchan S, et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 2000; 46: 107– 113.MEDLINE 34 Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, Gutfreund K, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32: 129– 134.MEDLINE 35 Tassopoulos N, Hadziyannis S, Cianciara J, Rizzetto M, Schiff ER, Pastore G, Rutkiewicz V, et al. Entecavir is effective in treating patients with chronic hepatitis B who have failed lamivudine therapy [Abstract]. Hepatology 2001; 34(Part 2): 340A. 36 Dunkle LM. ACH-126, 443: a second generation anti-HBV and anti-HIV L-nucleoside analogue [Abstract]. Antiviral Res 2001; 52(Suppl): 47. 37 Perrillo R., Schiff E, Hann H-WL, Buti M, Strasser S, Watkins KM, Moorat AE, et al. The addition of adefovir dipivoxil to lamivudine in decompensated chronic hepatitis B patients with YMDD variant HBV and reduced response to lamivudine—Preliminary 24 week results [Abstract]. Hepatology 2001; 34(Part 2): 349A. Citing Literature Volume36, Issue5November 2002Pages 1041-1045 ReferencesRelatedInformation
Referência(s)